Publications by authors named "N A de Glas"
Introduction: Immunotherapy with checkpoint inhibition (ICI) is increasingly prescribed to older patients with cancer. High age, especially in combination with frailty, has been associated to immune senescence, which is the age-related decline in immune function, thereby possibly hindering ICI effectiveness. This cross-sectional study aimed to assess whether blood cell immune senescence markers are associated with age, frailty and response to anti-PD-1 treatment in older patients with metastatic melanoma.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the Glasgow Prognostic Score (GPS), which combines albumin and C-reactive protein levels, as a tool for assessing health issues and mortality in older cancer patients.
- It finds that older patients with abnormal GPS are more likely to be frail and have higher one-year mortality rates compared to those with normal GPS.
- The GPS also enhances the predictive accuracy for mortality risk when combined with other clinical factors, indicating its potential usefulness in cancer treatment decisions for older adults.
Background: Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of particular interest due to comorbidities and frailty, which may impact their ability to tolerate irAEs and benefit from anti-PD-1 therapy. This study aimed to explore associations between clinical parameters and the occurrence of grade ≥ 3 irAEs and recurrence-free survival (RFS) in older patients with radically resected stage III/IV cutaneous melanoma treated with adjuvant anti-PD-1 therapy.
View Article and Find Full Text PDF